Malignant neoplasm of bilateral ovaries
ICD-10 C56.3 is a billable code used to indicate a diagnosis of malignant neoplasm of bilateral ovaries.
C56.3 refers to malignant neoplasms affecting both ovaries, which are classified under gynecologic malignancies. This condition is characterized by the uncontrolled growth of abnormal cells in the ovarian tissue, leading to the formation of tumors that can invade surrounding tissues and metastasize to other parts of the body. The diagnosis is often confirmed through imaging studies, such as ultrasound or CT scans, and histopathological examination of biopsy samples. Staging of ovarian cancer is crucial for determining the extent of disease and guiding treatment options. The FIGO (International Federation of Gynecology and Obstetrics) staging system is commonly used, ranging from Stage I (tumor confined to the ovaries) to Stage IV (distant metastasis). CA-125, a tumor marker, is frequently utilized in monitoring treatment response and disease recurrence. Surgical approaches may include bilateral salpingo-oophorectomy, where both ovaries and fallopian tubes are removed, often accompanied by staging laparotomy to assess the spread of cancer. Chemotherapy and targeted therapies may follow surgery, depending on the stage and histological type of the tumor.
Detailed pathology reports, imaging studies, and surgical notes are essential.
Diagnosis and management of ovarian cancer, staging laparotomy, and chemotherapy administration.
Ensure accurate coding of all procedures and treatments, including any adjuvant therapies.
Clear imaging reports indicating the presence of tumors and staging.
Pre-operative imaging for staging and post-operative follow-up imaging.
Radiology reports should correlate with surgical findings and pathology results.
Used for surgical treatment of C56.3.
Operative report detailing the procedure and findings.
Ensure alignment with gynecologic oncology standards.
CA-125 is a tumor marker used to monitor treatment response and disease recurrence in ovarian cancer. Accurate documentation of CA-125 levels is essential for coding C56.3, as it provides critical information about the patient's condition.
